Herb Cross

Herb Cross has more than 20 years of experience in executive leadership roles with responsibility for strategic financial management and corporate operations. His experience includes Chief Financial Officer roles at a number of life sciences companies including ARMO BioSciences, Balance Therapeutics, KaloBios Pharmaceuticals, and Affymax. Earlier in his career, he also served as Vice President of Finance at Neoforma, PDL BioPharma, and Facet Biotech. While at ARMO BioSciences, Herb led all administrative functions and corporate development in driving their successful 2018 initial public offering as well as the subsequent acquisition of the company by Eli Lilly for $1.6 billion. Herb received a B.S. in Business Administration from the University of California, Berkeley, and is a certified public accountant.